| 1 | Association between Fine Particulate Matter Exposure and Cerebrospinal Fluid |
|----|--|
| 2 | Biomarkers of Alzheimer's Disease among a Cognitively Healthy Population-based |
| 3 | Cohort |
| 4 | Emma Casey ¹ , Zhenjiang Li ² , Donghai Liang ^{1,2} , Stefanie Ebelt ^{1,2} , Allan I. Levey ³ , James J. Lah ³ , |
| 5 | Thomas S. Wingo ^{3,4} , Anke Hüls ^{1,2} |
| 6 | |
| 7 | ¹ Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA |
| 8 | ² Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory |
| 9 | University, Atlanta, GA, USA |
| 10 | ³ Department of Neurology, School of Medicine, Emory University, Atlanta, GA, USA |
| 11 | ⁴ Department of Human Genetics, School of Medicine, Emory University, Atlanta, GA, USA |
| 12 | |
| 13 | Corresponding author: |
| 14 | Anke Hüls, PhD |
| 15 | Rollins School of Public Health, Emory University |
| 16 | 1518 Clifton Road, Atlanta, GA, 30322 |
| 17 | E-mail: anke.huels@emory.edu |
| 18 | |
| 19 | Funding and Sources of support: This work used data collected by the Emory Healthy Brain Study |
| 20 | and was supported by the National Institute on Aging (NIA) [R01AG070937 (Lah) and |
| 21 | R01AG079170 (Hüls/Wingo)] and a HERCULES Pilot Project via National Institute of Environmental |
| 22 | Health Sciences (NIEHS) P30ES019776 (Hüls). The traffic-related air pollution exposure |
| 23 | assessment was supported by Pilot Grant via NIA P50AG025688 (Hüls/Liang) and the NIH grant |
| 24 | R21ES032117 (Liang). |
| 25 | |
| 26 | Acknowledgments: We would like to thank Liuhua Shi and her team who provided us with |
| 27 | guidance for the air pollution assignments of ambient $PM_{2.5}$. We also want to thank Dr. Jeremy A. |
| 28 | Sarnat (Emory), Dr. Armistead Russell (Georgia Tech), Ms. Kyung-Hwa Kim, and Ms. Abby Marinelli |
| 29 | from the Atlanta Regional Commission for providing data and guidance towards the traffic-related air |
| 30 | pollution exposure assessment. |
| 31 | |
| 32 | Conflicts of interest: The authors declare they have nothing to disclose. |

33 Abstract

34

Background: Epidemiological evidence suggests air pollution adversely affects cognition and
 increases the risk of Alzheimer's disease (AD), but little is known about the biological effects of fine
 particulate matter (PM_{2.5}) on early predictors of future disease risk.

38

Objectives: We investigated the association between 1, 3, and 5-year exposure to ambient and
 traffic-related PM_{2.5} and cerebrospinal fluid (CSF) biomarkers of AD.

41

42 **Methods:** We conducted a cross-sectional analysis using data from 1,113 cognitively healthy adults

43 (aged 45-75 years) from the Emory Healthy Brain Study in Georgia, USA. CSF biomarker

44 concentrations of A β_{42} , tTau, and pTau, were collected at enrollment (between 2016-2020) and

45 analyzed with the Roche Elecsys system. Annual ambient and traffic-related residential PM_{2.5}

46 concentrations were estimated at a 1km and 250m resolution, respectively, and 3- and 5-year

47 average exposures were computed for each participant based on time of specimen collection.

48 Associations between PM_{2.5} and CSF biomarker concentrations, considering continuous and

49 dichotomous (dichotomized at clinical cut-offs for AD-biomarker positivity) outcomes, were estimated

50 with multiple linear/logistic regression, respectively, controlling for potential confounders (age,

51 gender, race/ethnicity, body mass index, and neighborhood socioeconomic status).

52

Results: Interquartile range (IQR; IQR=0.845) increases in 1-year [β : -0.101; 95%-confidence

54 interval (CI): -0.18, -0.02] and 3-year (β : -0.078; 95%-CI: -0.15, -0.00) ambient fine PM_{2.5} exposures

so were negatively associated with A β_{42} CSF concentrations. Associations between ambient PM_{2.5} and

56 A β_{42} were similar for 5-year estimates, but not significant (β : -0.076; 95%-CI: -0.160, 0.005).

57 Dichotomized CSF variables revealed similar and significant associations between ambient PM_{2.5}

and A β_{42} . Associations with traffic-related PM_{2.5} were similar but not significant. PM_{2.5} exposures

59 were not associated with tTau, pTau, tTau/A β_{42} , or pTau/A β_{42} levels at enrollment.

60

61 **Conclusion:** In our cross-sectional study, PM_{2.5} exposure was associated with a significant

62 decrease in CSF A β_{42} which suggests an accumulation of amyloid plaques in the brain and an 63 increased risk of developing AD.

64

65 300/300

66 Introduction

67

68 As life expectancy rises and the U.S. population pyramid continues to age, we are seeing an 69 increase in chronic non-communicable age-related conditions, including Alzheimer's disease and 70 related dementias (AD/ADRD). With the multifactorial nature of AD pathogenesis, building evidence 71 around preventable environmental exposures may ultimately reduce inequities and improve health 72 outcomes. In this regard, accumulating epidemiological evidence demonstrates an association 73 between exposure to air pollution and the prevalence of AD/ADRD. Most of the evidence to date has 74 focused on links between fine particulate matter ($PM_{2.5}$), a mixture of fine particles in the air, and 75 cognitive function, incident cognitive impairment, or dementia.¹⁻⁴ Incident dementia is often studied 76 using diagnostic codes on insurance billing claims and medical records, facilitating studies with large 77 sample sizes; however, billing data are known to miss true dementia cases^{1,5} and there are no 78 diagnostic codes for the preclinical stages of dementia. In addition, PM_{2.5} can pass through the lung-79 gas-blood barrier, the gut-brain axis or directly enter brain tissue via the olfactory nerve to promote 80 oxidative stress and inflammation, processes directly related to the characteristic pathology of AD.6.7 81 Since PM_{2.5} is a heterogeneous mixture, different sources of exposure often have varying degrees of 82 toxicity and most existing studies have focused on ambient exposure, rather than those merely from traffic-related emissions. Understanding the impact of PM25, from both ambient and traffic-related 83 84 sources, on preclinical stages of dementia in older at-risk adults is crucial from a public health perspective, as it will improve the estimation of the burden of disease in association with air pollution 85

86 by identifying more affected individuals.

87

Recent systematic reviews highlight the need to expand the scope of current studies on air pollution 88 and dementia risk to include neuropathologically relevant outcomes, such as early indicators of 89 90 dementia, including AD cerebrospinal fluid (CSF) and plasma-based biomarkers, which can be assessed at the late stage of the preclinical phase.^{1.4.8} A recent study found positive associations 91 between PM_{2.5} and amyloid β -protein (A β)1-40 from plasma in longitudinal analyses, but no 92 93 associations were detected between PM_{2.5} and A β 1-42 or the ratio of A β 1-42/A β 1-40.⁹ Blood-based 94 biomarkers of protein pathology are less predictive of brain pathology and have shown insignificant changes in A β levels as compared to CSF A β biomarkers in AD patients.¹⁰ In this light, three 95 clinically validated CSF biomarkers: $A\beta_{42}$, total tau (tTau), and phosphorylated tau (pTau) have been 96 97 noted as valid proxies for neuropathological changes of AD, $\frac{8.11}{2}$ and specifically, A β_{42} has been linked to the abnormal pathologic state of cerebral A β in both animal and human models. Since 98 99 pathological changes related to AD can begin decades before symptoms appear, 12 quantifying the relationship between both ambient and traffic-related PM_{2.5} pollution and CSF biomarkers reflective 100 101 of AD-positive changes will elucidate how exposure influences dementia risk.¹³ 102

So far, two epidemiological studies have reported associations between PM_{2.5} and Aβ₄₂ in cognitively 103 healthy individuals whereas no relationships with tTau or pTau have been noted.^{14, 15} However, there 104 105 are several limitations with these prior studies, including 1) the exposure assessments in Alemany et al. (2021) and Li et al. (2022) only focused on 1- or 2-year average PM_{2.5} prior to the biomarker 106 107 assessment; 2) the relatively small sample size (N=156) in Alemany et al. (2021),¹⁵ and 3) the 108 outcome assessment in Li et al. (2022)¹⁴ which relied on the Innotest-AMYLOID(1-42) ELISA assay, an unstandardized manual method, showing a high correlation with the automated Elecsvs® method 109 110 but higher intra- and inter-laboratory variations.^{16, 17}

112 To address these limitations in prior studies and grow our understanding of the impact of air pollution

on preclinical dementia risk, here, we characterized the cross-sectional association between long-

term ambient and traffic-related PM_{2.5} exposure (1, 3, and 5 years prior to biomarker assessment)

and CSF biomarker composition (A β_{42} , tTau, and pTau, assessed with Elecsys[®] AD CSF assays) in

a dementia-free, aging population, as part of the Emory Healthy Brain Study (EHBS). We also tested

for effect modification by several well-known risk factors for AD/ADRD-related outcomes, including

- 118 APOE- ϵ 4 status, the strongest genetic risk factor for AD.
- 119

120 Methods

121

122 Study Design and Population

123

124 The EHBS is a gerontology-based prospective research study focusing on the cognitive health of

125 older adults. The EHBS is nested within the Emory Healthy Aging Study (EHAS) and includes

participants from the metro-Atlanta region in Georgia, USA. Our cross-sectional analysis includes
 data from the baseline visits, which were conducted between 2016 and 2020. The primary aim of the

128 EHBS is to characterize psychological and psychosocial factors associated with normal and

abnormal aging through assessment of the central nervous system among adults 45-75 years old

130 who were free of cognitive impairment in addition to several other chronic conditions (e.g. congestive

heart failure, multiple sclerosis, HIV) at enrollment; more details on recruitment and eligibility have

- 132 been published elsewhere.¹⁸
- 133

134 Demographic characteristics were collected with the online Health History Questionnaire (HHQ).¹⁸

135 Individual-level information was self-reported for gender, age, race/ethnicity, educational attainment,

and residential address. Participants could choose one or more race(s) from a 5-item list

137 (White/Caucasian, Black/African American, Asian, American Indian/Alaska Native, Hawaiian/Other

138 Pacific Islander). Hispanic ethnicity (Yes/No) was addressed in a separate HHQ question. Data on

educational attainment were also self-reported with 7 possible categories ranging from less than

high school to professional or doctorate degree. EHBS biennial study visits include neuropsychology

tests, biospecimen collection (blood, cerebrospinal fluid), cardiovascular measures, and brain

imaging. All measures, including anthropometric, are collected by trained clinical research staff for
 use in the diagnosis and prediction of chronic illness.¹⁸

144

145 *PM*_{2.5} *Exposure Assessment*

146

147 Due to evidence suggesting a relationship between both ambient PM_{2.5} and traffic-related PM_{2.5}

148 exposure and cognitive decline, and because traffic-related PM_{2.5} is a major exposure source in

149 urban environments like Atlanta, GA,¹⁹ we used both measures of $PM_{2.5}$ in our analyses.

150

151 We obtained ambient PM_{2.5} exposure data from the publicly available Socioeconomic Data and

152 Application Center (SEDAC) air quality data set for health-related applications.²⁰ The data set

153 consists of yearly ambient $PM_{2.5}$ levels (in $\mu g/m^3$) estimated at a 1 km spatial resolution using a well-

validated ensemble-based prediction model for the contiguous United States (2000-2016). As

described by Di *et al.* (2019), three machine-learning algorithms: random forest, neural network, and

gradient boosting, were used to predict ambient $PM_{2.5}$ and included a variety of predictor variables

157 from satellite data, land use, meteorological variables, and chemical transport model simulations. ²¹

The ensemble model then combined these $PM_{2.5}$ predictions with a generalized additive model that allowed for the contribution of each machine-learning algorithm to vary by location.²¹ The ensemble model was trained on $PM_{2.5}$ levels measured at 2,156 U.S. EPA monitors, validated with 10-fold

- 161 cross-validation, and produced high-resolution annual PM_{2.5} predictions with an average R² of 0.89.²¹
- 162

As described previously,²² traffic-related PM_{2.5} exposure concentrations (in $\mu g/m^3$) for the metro-163 164 Atlanta area for the period 2002 to 2019 were generated by two approaches. Briefly, for the 2002-165 2011 period, annual traffic-related PM_{2.5} concentrations at 250 m resolution were generated by the Research LINE-sources dispersion (R-LINE) model and calibrated by measurements from local 166 167 PM_{2.5} ground monitoring sites.^{23,24} For the 2012-2019 period, annual traffic-related PM_{2.5} 168 concentrations at 200-250 m resolution were predicted via a land-use random forest model built on training data comprised of the 2015 annual concentrations of traffic-related PM_{2.5} from Atlanta 169 170 Reginal Commission, road inventory and traffic monitoring data based on measurements from the 171 Georgia Department of Transportation which considered road geometry and traffic volume, land cover data from the National Land Cover Database, and ambient PM_{2.5} data from Atmospheric 172 Composition Analysis. The random forest model was trained with the R package randomForest. The 173 174 resulting 200-250m resolution annual traffic-related $PM_{2.5}$ predictions had an average R² of 0.80. Both databases had spatial coverage of approximately 20 counties in GA. Given the reduced 175 coverage of the traffic-related PM_{2.5} exposure estimates compared to the ambient PM_{2.5} data and the 176 geographic spread of our study population, the analysis sample for these models included only the 177 178 participants located within the metro-Atlanta area.

179

180 For both ambient and traffic-related exposures, we spatially matched geocoded residential

addresses to the closest centroid of grids (based on 1 km² or 200-250 m² grids) to assign annual

exposures. We then calculated individual 3- and 5-year exposures by averaging yearly predictionsprior to specimen collection.

184

185 AD CSF Biomarker Concentrations

186

CSF biospecimens were collected by EHBS research staff via lumbar puncture, CSF collection 187 protocol has been previously described.²⁵ A β_{42} , tTau, and pTau CSF levels were quantified using the 188 ElectroChemiLuminescense Immunoassay (ECLIA) Elecsys® AD CSF portfolio on an automated 189 Roche Diagnostics instrument (F. Hoffman-La Roche Ltd). The assays have measuring ranges of 190 191 200–1700 pg/mL (A β_{42}), 80–1300 pg/mL (tTau) and 8–120 pg/mL (pTau). tTau and pTau levels were log-base₁₀ transformed for normality in linear models in the statistical analyses. We also examined 192 CSF biomarker ratio outcomes, namely, tTau/A β_{42} and pTau/A β_{42} , which are highly predictive of 193 194 amyloid positivity based on concordance with amyloid-PET, including for cognitively normal 195 participants.²⁶ All AD CSF biomarker outcomes were kept as continuous variables for linear 196 regression analyses and separately dichotomized based on the Elecsys® AD CSF portfolio positive 197 (+) cut-offs for logistic regression analyses (A $\beta_{42} \le 1030$ pg/mL; tTau >300 pg/mL; pTau >27 pg/mL; tTau/A β_{42} >0.28pg/mL; pTau/A β_{42} >0.023pg/mL).^{8.27} The cut-off values for A β_{42} , tTau/A β_{42} , and 198 pTau/AB42 CSF were established and validated to demonstrate CSF biomarker concordance with 199 200 amyloid-β PET visual read in the BioFINDER and ADNI studies, respectively.²⁸ Cut-off values for 201 single tau biomarkers, tTau and pTau, were derived and validated in a separate study based on the separation between mild cognitive impairment (MCI) patients with a higher versus lower risk of 202 203 cognitive decline, and optimized for identification of AD patients versus normal controls.²⁹

204

205 Covariates

206

207 Sources of potential confounding were identified with a directed acyclic graph (DAG; Figure S1). Individual-level confounders were conceptualized as factors impacting both residential PM_{2.5} 208 209 exposure and the outcome measure. Potential confounding factors included in the analysis were 210 gender, age, neighborhood socioeconomic status (N-SES), race/ethnicity, educational attainment, 211 and body mass index (BMI). Due to historic racism and discriminatory land-use practices such as redlining, environmental exposures disproportionately affect low-income and minority populations. 212 213 For this reason, neighborhood deprivation characteristics were also included as potential 214 confounding variables and effect modifiers as done in our previous work.³⁰ Race has also been noted as an important factor when interpreting CSF biomarker results.³¹ In addition, BMI influences 215 biomarker concentrations and is also related to N-SES through characteristics such as neighborhood 216 walkability, greenspace, and food access. 32, 33 217 218 219 Due to the presence of multi-ancestral groups and small categories in self-reported race/ethnicity, 220 we used a 3-level race variable in the analysis: White/Caucasian, Black/African American, and Other, as well as a dichotomous ethnicity variable indicating Hispanic origin. Similarly, educational 221 attainment was included as a 3-level variable: master or higher, college, less than college. Height 222 223 and weight measurements were used to calculate body mass index (BMI, weight in kilograms 224 divided by height in meters squared) which was used as a continuous variable in all models. N-SES for each participant was established in this study with census-tract level American Community 225 Survey (ACS) defined principal components of neighborhood deprivation (see Li et al.³⁰ for details) 226 227 and the Area Deprivation Index (ADI). As described previously in Li et al., ³⁰ three principal 228 components of neighborhood deprivation were calculated based on estimates for 5-year ACS 229 census-tract-level data, including 16 indicators of six socioeconomic domains (poverty/income, racial 230 composition, education, employment, occupation, and housing properties) (Figure S2).³⁰ The ADI is provided in national percentile rankings at the block group level from 1 to 100, where 100 represents 231 the most deprived neighborhood, and was calculated using census block group-level indicators and 232

factor analysis to cluster indicators based on their ability to explain the variance between block groups. $\frac{34}{2}$

235

236 Statistical Analyses

237

238 We implemented multiple linear and logistic regression models to estimate the relationship between 239 residential PM_{2.5} exposure and AD CSF biomarker levels at enrollment. In these models, biomarker 240 concentrations (linear regression models) or dichotomized AD positive variables (logistic regression 241 models) were assigned as dependent variables and $PM_{2.5}$ exposures along with the selected 242 confounding variables as independent variables. Since the biomarkers were measured on the same scales, but with different ranges, we standardized all continuous biomarker measures by converting 243 244 them to z-scores prior to employing regression analysis to increase comparability of results across 245 different biomarkers. Z-scores were computed for each observation by subtracting the sample mean from each individual value and subsequently dividing by the sample standard deviation. Further, we 246 247 standardized the $PM_{2.5}$ estimates according to its distribution by dividing all $PM_{2.5}$ exposures of interest by the IQR of 1-year ambient or traffic-related PM_{2.5} exposure respectively. The general form 248

of the model for all analyses appears below:

| 250 | |
|-----|---|
| 251 | AD CSF Biomarker Outcome = $\alpha_0 + \beta_1 P M_{2.5} + \gamma_1 Age + \gamma_2 Gender + \gamma_3 Education +$ |
| 252 | $\gamma_4 Ethnicity + \gamma_5 BMI + \gamma_6 ADI + \gamma_7 nSES PC_1 + \gamma_8 nSES PC_2 + \gamma_9 nSES PC_3 + \varepsilon$ |
| 253 | |
| 254 | Where $PM_{2.5}$ represents either ambient or traffic-related $PM_{2.5}$ averages 1, 3, or 5 years prior to |
| 255 | specimen collection and ϵ represents the random error term, with an assumed mean of zero and |
| 256 | constant variance $\sim N(0, \sigma^2)$. |
| 257 | |
| 258 | Effect Modification Analyses |
| 259 | |
| 260 | We tested for effect modification by several well-established risk factors for AD, adding an |
| 261 | interaction term between PM _{2.5} and each risk factor in individual regression models. These risk |
| 262 | factors included whether a participant had at least one APOE-ε4 allele, family history of AD |
| 263 | (indicated by parent or first-sibling diagnosis), gender, age, and ADI. Despite a hypothesized |
| 264 | additive genetic effect of the ɛ4 allele, statistical interaction was assessed dichotomously due to the |

- additive genetic effect of the ε 4 allele, statistical interaction was assessed dichotomously due to the small number of homozygous ε 4 carriers (2.1%; **Table 1**). Family history of AD (no/yes), gender
- (male/female), and ADI (<50/ \geq 50) were also added as dichotomous variables while interaction with
- 267 age was assessed continuously. Using the models with interaction, we then tested for effect
- 268 modification with the *interplot* R package and n=100,000 simulations.
- 269
- For all statistical analysis, we used R Statistical Software version 4.2.2, and the significance level α =0.05.
- 272
- 273 **Results**
- 275 Study Population
- 276

274

277 After excluding EHBS participants with missing demographic data (n=46), the analytic sample 278 included 1,113 individuals (Table 1). Participants lived primarily around the Atlanta metropolitan 279 area, spanning 489 census blocks in the state of Georgia (detailed neighborhood characteristics are summarized in Table S6). The average age of our sample was 61.7 years (SD=6.73), 69.9% were 280 281 females, and 84.7% identified as White/Caucasian, 10.9% identified as Black/African American, and only 2.9% identified as Hispanic. The average BMI was 25.5 kg/m² (SD=3.55). Our sample was 282 highly educated with 86.7% having received an associate degree or higher. The ADI was right 283 skewed with a median of 25, indicating half of the sample is in 25% lower deprivation than the 284 285 national average.

286

287 There was spatial variability in ambient PM_{2.5} levels in our study area, with the highest quintile of exposure (10.1-13.21 µg/m³) localized to the south of the city of Atlanta and lowest guintile of 288 289 exposure (5.63-8.98 µg/m³) localized to communities north of Atlanta such as Marietta and Roswell (Figure 1, Table 1). Traffic-related PM_{2.5} exposure levels had lower concentrations (since we only 290 291 estimated the traffic-related component of $PM_{2,5}$) but higher variability with annual average 292 exposures of 1.15 µg/m³ (SD=0.46) compared with annual average ambient exposures of 9.52 293 $\mu q/m^3$ (SD=0.76). Traffic-related PM_{2.5} estimates had a maximum of 5.10 $\mu q/m^3$ and these levels 294 were localized exclusively to the city of Atlanta. Annual ambient and traffic-related PM_{2.5} exposure

concentrations were weakly correlated (Pearson correlation = 0.36). More details on the distribution

of and relation between ambient and traffic-related PM_{2.5} exposure concentrations are provided in
 the supplemental material (Figures S3 and S4).

298

299 We observed a wide spread of concentrations for CSF A β_{42} in the study population (median A β_{42} level = 1210, IQR = 692.3). A β_{42} concentrations did not show a major departure from normality, 300 except for the highest level which had a very high frequency, indicating normal A_{β42} concentrations 301 302 in most participants, but tTau and pTau distributions were skewed (Figure S5). After log 303 transformation, Tau concentrations were approximately normally distributed (Figure S6). 304 Approximately 36% of participants had A β_{42} concentrations less than or equal to 1030 pg/mL which corresponds, on average, to a positive reading for AD as indicated by Elecsys[®] AD CSF portfolio 305 positive (+) cut-offs. We observed AD positive readings for tTau and pTau cut-offs in 6% of the study 306 307 population. Based on the pTau/A β_{42} ratio AD (+) positive cut-off, we detected amyloid-positivity in 308 10.6% of participants. Details on the distributions of AD CSF biomarker concentrations and the 309 frequency of biomarker-positivity detected among participants are provided in Table 2. 310 311 *PM*_{2.5} and *AD* CSF biomarkers 312 313 Among the continuous AD CSF biomarkers, higher levels of 1- and 3-year ambient PM₂₅ exposures 314 were associated with lower A β_{42} CSF concentrations at baseline after adjusting for potential confounding variables (Figure 2A). Specifically, an IQR (0.845 µg/m³) increase in the 1- or 3-year 315 316 ambient PM_{2.5} exposure was significantly associated with a -0.09 (95% CI: -0.15, -0.02) and -0.07 317 (95% CI: -0.13, -0.005) decrease in A β_{42} CSF z-score, respectively, after confounder-adjustment. 318 The associations of 5-year ambient PM_{2.5} (Figure 2A) and traffic-related PM_{2.5} (Figure 2F) and A β_{42} 319 CSF were similar, but not significant. No significant associations were detected between ambient 320 (Figure 2B-E) or traffic-related (Figure 2G-J) $PM_{2.5}$ exposures and tTau, pTau, tTau/A β_{42} , or 321 pTau/A β_{42} CSF concentrations at enrollment, but associations with tTau/A β_{42} and pTau/A β_{42} were

- similar to those of A β_{42} and consistent with AD-related pathology (**Figure 2I-J**).
- 323

324 For the AD CSF biomarker positive cut-off outcomes, higher residential ambient PM_{2.5} exposures 325 were associated with increased prevalence of an AD positive (+) $A\beta_{42}$ portfolio reading at baseline 326 with statistically significant associations for an IQR (0.845 µg/m³) increase in 1-year (OR=1.23; 95% 327 Cl: 1.07, 1.42), 3-year (OR=1.20; 95% Cl: 1.04, 1.37), and 5-year (OR=1.21; 95% Cl: 1.04, 1.40) 328 average ambient $PM_{2.5}$ exposure (**Figure 3A**). The associations between traffic-related $PM_{2.5}$ 329 exposures and an AD positive (+) $A\beta_{42}$ portfolio reading at enrollment were similar but not significant 330 (Figure 3F). We further observed significant associations between 3- and 5-year traffic-related PM_{2.5} 331 exposures and an AD (+) pTau/A β_{42} ratio reading at enrollment, but not for 1-year traffic-related PM_{2.5} exposure (Figure 3J) or ambient PM_{2.5} exposure (Figure 3E), and while not significant, these 332 results were consistent with those of tTau/A β_{42} (Figure 3I, Figure 3D). We did not observe 333 statistically significant associations between ambient (Figure 3B-C) or traffic-related (Figure 3G-H) 334 PM_{2.5} exposures and AD positive (+) tTau or pTau cut-offs.

335 336

The associations between ambient $PM_{2.5}$ and $A\beta_{42}$ CSF concentrations and AD positive (+) $A\beta_{42}$

- portfolio reading remained significant even after restricting our sample size to only those located in
- the metro-Atlanta area (**Figure S7, Tables S1, S2,** and **S3**), which is the subsample for which traffic-
- related $PM_{2.5}$ exposures estimates were available (sample size reduced from $N_{ambient}$ =1,113 to $N_{traffic}$ =1,080).
- 342
- 343 Effect modification by other common risk factors for AD
- 344

The association of annual average ambient PM_{2.5} exposure and concentrations of A β_{42} CSF was not significantly modified by *APOE*- ϵ 4 carriership (p = 0.59), AD family history (p = 0.37), ADI (p = 0.62)

or gender (p = 0.67) (Figure 4A-D, Table S4). Similarly, the association of annual average ambient PM_{2.5} exposure and AD positive (+) A β_{42} portfolio reading was not significantly modified by APOE- ϵ 4

carriership (p = 0.80), AD family history (p = 0.27), ADI (p = 0.12) or gender (p = 0.72) (**Figure S8A**-

350 **D, Table S5**). Effect modification by age was also not statistically significant (p=0.17), but we

observed an increasing negative effect of PM_{2.5} on A β_{42} CSF levels with increasing age, and

- significant associations between PM_{2.5} and A β_{42} CSF levels starting around 60 years of age (Figure
- 353 **<u>4E</u>**); a similar pattern was revealed when looking at the stratified effects of PM_{2.5} on AD positive (+)
- A β_{42} portfolio reading by age (interaction p=0.34) (**Figure S8E**).
- 355 356

357 **Discussion**

358

359 In the present study, we examined the impacts of both ambient PM_{2.5} exposure and traffic-related PM_{2.5}, a major source of ambient PM_{2.5} in urban environments, on CSF biomarkers of AD in 1,113 360 361 cognitively healthy individuals. Our findings show associations between long-term ambient PM_{2.5} 362 concentrations and decreased A_{β42} AD CSF biomarker concentrations (significant for 1- and 3-year 363 average exposures), as well as increased likelihood of an A β_{42} AD (+) positive portfolio reading 364 (significant for 1-, 3- and 5-year average exposures). We further found significant associations between 3- and 5-year traffic-related $PM_{2.5}$ exposure estimates and a pTau/A β_{42} (+) positive portfolio 365 reading at enrollment, but not with ambient PM₂₅ exposure. We found no associations between 366 367 ambient or traffic-related PM2.5 exposures and pTau or tTau continuous concentrations or their ratios with A β_{42} , however, the directions of effect for pTau/A β_{42} and tTau/A β_{42} continuous ratio outcomes 368 were consistent with AD-related amyloid pathology. Further, while not statistically significant, the 369

370 strength of the association between annual ambient $PM_{2.5}$ exposure and $A\beta_{42}$ AD CSF 371 concentrations differed by age and was particularly pronounced for individuals over the age of 60.

372

The observed associations between $PM_{2.5}$ exposure and the A β_{42} AD CSF biomarker as well as

pTau/A β_{42} positive portfolio readings, which are equally predictive of amyloid PET status (+/-) as A β

ratio outcomes,³⁵ among cognitively healthy older adults is consistent with evidence from existing
 literature. Signs of AD can be detected in the early stages of the AD continuum,¹⁷ and decreases in

CSF concentrations of A β_{42} (a marker of amyloidosis) and elevation in tau species (phosphorylated

and total tau) are well-established as pathogenic biomarkers in AD diagnosis.³⁶ To date, there have

been few studies estimating the effects of $PM_{2.5}$ exposure on certified biomarkers of AD in healthy,

aging populations. One study found a similar relationship between air pollution exposure and A β_{42} ,

although they used CSF A $\beta_{42/40}$ ratio to reflect A β pathology rather than the individual biomarker

measurements.¹⁵ Their estimates were similarly negative, but did not reach significance, likely owing

to the relatively small sample size (N=147).¹⁵ Another study¹⁴ found a statistically significant total

effect of ambient PM_{2.5} on A β_{42} CSF as well as pTau/A β_{42} concentrations among N=1,131

cognitively healthy older individuals, which was further mediated by a CSF biomarker of

387

388 We found mostly null associations between 1-, 3-, and 5-year average ambient and traffic-related

PM_{2.5} exposures and tTau as well as pTau concentrations at enrollment, except for the model with 3 year ambient PM_{2.5} and tTau levels, in which we found a significant negative association. The

year amplent PM2.5 and that levels, in which we found a significant negative association. The

direction of estimates for tau biomarkers are expected to be positive for AD-related change.

Associations between $PM_{2.5}$ and tau biomarkers diminished when taking AD CSF cut-offs into account, suggesting that the negative association with the continuous tTau levels was a false

³⁸⁶ neuroinflammation, sTREM2.¹⁴

positive finding. Other studies examining the associations between air pollution and CSF biomarkers of AD in cognitively healthy adults report similar findings, where both Alemany *et al.* (2021) and Li *et al.* (2022) found null associations between $PM_{2.5}$ and pTau as well as tTau CSF concentrations.^{14, 15}

397

Stronger associations were detected between ambient PM_{2.5} and AD CSF biomarkers as compared 398 with traffic-related PM_{2.5} exposure. Ambient PM_{2.5} contains emissions from traffic, industry, domestic 399 400 fuel burning, natural sources including soil dust and sea salt, as well as unspecific sources of human 401 origin. $\frac{37}{2}$ On the other hand, traffic-related PM_{2.5} is a source of ambient PM_{2.5} that includes emissions 402 of organic and inorganic gaseous PM precursors from the combustion of fuels and lubricants.³⁷ 403 Since both sources contain organic and often toxic particles, we expected to see relationships between both sources of PM_{2.5} and AD CSF biomarkers, and while not significant for A β_{42} , the 404 405 associations between traffic-related PM2.5 and AD CSF biomarkers were similar to associations with

- ambient $PM_{2.5}$. More research needs to be done to determine which $PM_{2.5}$ mixtures are particularly harmful to the central nervous system.
- 408

409 While we did not find effect modifications by *APOE*-ε4 carriership or other common risk factors for

AD, the association between ambient $PM_{2.5}$ exposure and $A\beta_{42}$ CSF became stronger with

411 increasing age (though not statistically significant). These results could suggest that AD CSF

biomarkers might not be sensitive enough to detect AD-related changes in participants < 60 years

old, but more research in the population will clarify the most clinically relevant age for biomarker

414 measurement. Previous research suggests that biomarker patterns of A β_{42} consistent with stage 1

AD (amyloid pathology only) are first detectable during early middle age (45-54 years), while increases in tTau and pTau are typically not apparent until later (ages \geq 55 years).³⁸ However, this

417 previous study used an unstandardized assay, the INNOTEST ELISA, which often yields systematic

418 variability in comparison to the Elecsys assay. Another potential explanation for the stronger

419 associations among participants older than 60 years could be the higher accumulative PM_{2.5}

420 exposure over the lifetime among older individuals. In line with this hypothesis, one study examining

421 the relationship between $PM_{2.5}$ exposure and AD prevalence found a stronger effect of $PM_{2.5}$ on AD

- 422 prevalence among those at or above 70 years of age.3
- 423

424 There are several strengths to be noted, such as, the exposure assessment which included two 425 sources of PM_{2.5}, ambient and traffic-related, which were estimated at a high spatial resolution of up 426 to 200m; our outcome assessment which relied on a recommended assay for AD CSF biomarker 427 measurement.¹⁶ and for which we observed consistent associations using continuous biomarker 428 concentrations as well as AD positivity cut-offs; our inclusion of several well-known confounders and 429 methods to reduce confounding by neighborhood-level characteristics; and our relatively large 430 sample size (N=1,113) of CSF measurements from cognitively healthy older adults free of chronic 431 illness.

432

In addition to its strengths, this study has several limitations. Given that ADRD progresses over the 433 course of several years or decades, we evaluated the associations with 3- and 5-year average $PM_{2.5}$ 434 concentrations prior to enrollment in addition to the 1-year averages. However, given that exposure 435 436 was assigned based on the baseline residence and some participants could have relocated in the 437 years prior to the study, the 3- and 5-year estimates may be affected by exposure misclassification. 438 Such exposure misclassification is also a potential explanation for the weaker associations between 439 the 3- and 5-year PM_{2.5} exposures and A β_{42} CSF concentrations in comparison to the 1-year exposure concentrations. Our study also only used cross-sectional CSF measurements; longitudinal 440 repeated measures analyses may provide a better understanding of the long-term effect of air 441 pollution on CSF biomarker trajectories of AD. Further, our sample was not representative of the 442

- 443 Atlanta metropolitan area, the target population, as it was mainly high SES and white, which limits
- both the generalizability and transportability of our estimates. Finally, while we looked at two different
- 445 sources of PM_{2.5}, we did not examine the relationship between AD pathology and specific
- 446 components of PM_{2.5}. Future studies should consider the components of PM_{2.5} as they are dynamic
- 447 between ambient and traffic-related sources with different toxicity³⁹ and could reveal important and
- 448 undiscovered relationships between exposure and disease pathogenesis.
- 449
- 450 In conclusion, our results suggest that exposure to ambient and traffic-related PM_{2.5}, even at levels
- 451 below current primary and secondary standards defined by the Environmental Protection Agency
- 452 (EPA) for PM_{2.5} (annual average standards with levels of 12.0 μ g/m³ and 15.0 μ g/m³, respectively),
- increases the risk of future AD development. Additionally, our results add to the growing body of
- evidence which suggests that air pollution directly contributes to neurodegeneration by accelerating
- 455 A β_{42} accumulation in the brain.^{2.40}

| Weuve, J., et al., <i>Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes:</i> <i>An Updated Systematic Review of the Epidemiological Literature.</i> Environ Health Perspect, 2021. 129(9): p. 96001. Thiankhaw, K., N. Chattipakorn, and S.C. Chattipakorn, <i>PM2.5 exposure in association with AD-</i> <i>related neuropathology and cognitive outcomes.</i> Environ Pollut, 2022. 292(Pt A): p. 118320. Yang, L., et al., <i>Associations between PM(2.5) exposure and Alzheimer's Disease prevalence</i> <i>Among elderly in eastern Chine.</i> Environ Health, 2022. 21(1): p. 119. Delgado-Saborti, J.M., et al., <i>A critical review of the epidemiological evidence of effects of air</i> <i>pollution on dementic, cognitive function and cognitive decline in adult population.</i> Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service</i> <i>beneficiaries, 2011-2013.</i> Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., <i>A revience of sepirable fine particulate matter (PM(2.5))-induced brain damage.</i> Front Mol Neurosci, 2022. 151: p. 95174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease.</i> Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>Nik-AA Research Framework: Toward a biological definition of Alzheimer's disease.</i> Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohart of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023.</i> 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Trans Neurodegener, 7202. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis,</i> | 456 457 | Refer | rences |
|---|------------|-------|---|
| An Updated Systematic Review of the Epidemiological Literature. Environ Health Perspect, 2021. 129(9): p. 96001. Thiankhaw, K., N. Chattipakorn, and S.C. Chattipakorn, PM2.5 exposure in association with AD- related neuropathology and cognitive outcomes. Environ Pollut, 2022. 292(Ft A): p. 118320. Yang, L., et al., Associations between PM(2.5) exposure and Alzheimer's Disease prevalence Among élderiy in eastern Chino. Environ Health, 2022. 21(1): p. 118. Delgado-Saborit, J.M., et al., A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiary. 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep. 2016. 4(S): p. 519-522. Hajat, A., et al., Alt pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory Study. Environ Int, 2023. 172: p. 107800. Klyucherew, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transi Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Jakovances in the development of new biomarkers of Alzheimer's disease. Trais Neurodegener, 2022. 11(1): p. 25. Batrels, C., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 1795-804. Bouwman, F.H., et al., Clinical and biomarkers of Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 9(11): p. 1752-1763. Bouwman, F.H., et al., Clinical and bio | 458 | 1. | Weuve, J., et al., Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: |
| 129(9): p. 96001. Thiankhaw, K., N. Chattipakorn, and S.C. Chattipakorn, PM2.5 exposure in association with AD- related neuropathology and cognitive outcomes. Environ Pollut, 2022. 292(Pt A): p. 118320. Yang, L., et al., Associations between PM(2.5) exposure and Alzheimer's Disease prevalence Among elderly in eastern China. Environ Health, 2022. 21(1): p. 119. Delgado-Saborit, J.M., et al., A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air polition and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transi Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Ansty), 2022. 14(1): p. e12314. Li, M., | 459 | | An Updated Systematic Review of the Epidemiological Literature. Environ Health Perspect, 2021. |
| Thiankhaw, K., N. Chattipakorn, and S.C. Chattipakorn, <i>PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes.</i> Environ Pollut, 2022. 292(Pt A): p. 118320. Yang, L., et al., <i>Associations between PM(2.5) exposure and Alzheimer's Disease prevalence Among elderly in eastern China.</i> Environ Health, 2022. 21(1): p. 119. Delgado-Saborit, J.M., et al., <i>A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population.</i> Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013.</i> Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., <i>A review of respirable fine particulate matter (PM(2.5))-induced brain damage.</i> Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease.</i> Biomed Rep, 2016. 4(5): p. 519-522. Hajat, A., et al., <i>Air pollution and plasma amyloid beto in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegnener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Uso of Crebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 137-148.</i> Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> Transl Neurodegnener, 2022. 11(1): p. 25. Bateman, R.J., et al., <i>Clinical anglication of CSF STREM2</i> in cognitively normal older adults: Evidence disease: From rationale to ratios. Alzheimers Disp. 2020. 78(3): p. 137-148. Bouwman, F.H., | 460 | | 129 (9): p. 96001. |
| related neuropathology and cognitive outcomes. Environ Pollut, 2022, 292(Pt A): p. 118320. Yang, L., et al., Associations between PM(2.5) exposure and Alzheimer's Disease prevalence Among elderly in eastern China. Environ Health, 2022, 21(1): p. 119. Delgado-Saborit, J.M., et al., A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., NA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherey, T.O., et al., Jack Orospinal Fluid Biomarkers of Alzheimer's Disease. Risk in Mild Cognitive Umpairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Batretas, C., et al., Clinical anplication of CSF sitomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (2021. 157): p. 105804. Bouwman, F.H., et al., Clinical application of CSF sitomarkers of Alzheimer's disease: From rationale to ratios. Alzheimers Dement (2022. 157): p. 227-33. Bouwman, F.H., et al., Clinical application of CSF sitomarkers of Alzheimer's diseases in cognitively unimpaired | 461 | 2. | Thiankhaw, K., N. Chattipakorn, and S.C. Chattipakorn, PM2.5 exposure in association with AD- |
| Yang, L., et al., Associations between PM(2.5) exposure and Alzheimer's Disease prevalence Among elderly in eastern China. Environ Health, 2022. 21(1): p. 119. Delgado-Saborti, J.M., et al., A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ, 2021. 577: p. 143734. Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., NN-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air pollution and plasma amyloid betto in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical and biomarker for Alzheimer's disease: From rationole to rotios. Alzheimers D | 462 | | related neuropathology and cognitive outcomes. Environ Pollut, 2022. 292 (Pt A): p. 118320. |
| Among elderly in eastern China. Environ Health, 2022. 21(1): p. 119. Delgado-Saborit, J.M., et al., <i>A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population.</i> Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiares,</i> 2011-2013. Alzheimers Dement, 2017. 31(1): p. 28-37. Li, W., et al., <i>A review of respirable fine particulate matter (PM(2.5))-induced brain damage.</i> Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease.</i> Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</i> Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkga Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyuchrev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegener, 2022. 11(1): p. 25. Batels, C., et al., <i>Uso of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.</i> J Alzheimer Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease:</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease:</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical and biomarker sof SIREM2 in cognitivel paramal older adults: The CABLE study.</i> Ann Clin Transl Neuro) 2022. 9(11): p. 1752-1763. Meamy, S. | 463 | 3. | Yang, L., et al., Associations between PM(2.5) exposure and Alzheimer's Disease prevalence |
| Delgado-Saborit, J.M., et al., <i>A critical review of the epidemiological evidence of effects of air</i> <i>pollution on dementia, cognitive function and cognitive decline in adult population.</i> Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service</i> <i>beneficiaries, 2012-2013.</i> Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., <i>A review of respirable fine particulate matter (PM(2.5))-induced brain damage.</i> Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Thang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease.</i> Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</i> Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 76(3): p. 1137-1148.</i> Bateman, R.J., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease:</i> From <i>rationole to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Associations between air pollution and Diomarkers of Alzheimer's disease: in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Dakterzada, F., et al., <i>Associations between air pollution and Diomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. | 464 | | Among elderly in eastern China. Environ Health, 2022. 21 (1): p. 119. |
| pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total Environ, 2021. 757: p. 143734. Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W. W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical and plication of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Associations between air pollution and biomarkers of Alzheimer's disease: in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assesciation of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al. | 465 | 4. | Delgado-Saborit, J.M., et al., A critical review of the epidemiological evidence of effects of air |
| Environ, 2021. 757: p. 143734. Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries</i>, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., <i>A review of respirable fine particulate matter (PM(2.5))-induced brain damage</i>. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease</i>. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</i>. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study</i>. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease</i>. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Juse of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148.</i> Battems, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</i>. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</i>. From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. 1752-1763. Alemany, S., et al., <i>Association between air pollution and CSF STREM2 in cognitively normal older adults: The CABLE study</i>. Ann Clin Transl Neurol, 2022. 9(1): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and Diomarkers of Alzheimer's disease in cognitively normal inder individuals</i>. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Clerebrospinal fluid biomarkers measured by Elecs</i> | 466 | | pollution on dementia, cognitive function and cognitive decline in adult population. Sci Total |
| Goodman, R.A., et al., <i>Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013.</i> Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., <i>A review of respirable fine particulate matter (PM(2.5))-induced brain damage.</i> Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease.</i> Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</i> Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.</i> J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rotionale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. 1752-1763. Alemany, S., et al., Association between air pollution and biomarkers of Alzheimer's disease in <i>cognitively unimpaired individuals.</i> Environ Int, 2023. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in <i>cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid im</i> | 467 | | Environ, 2021. 757 : p. 143734. |
| beneficiaries, 2011-2013. Alzheimers Dement, 2017. 13(1): p. 28-37. Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W. J., X. Zhang, and W. W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Ir., et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Batteman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical on fullition and CSF STREM2 in cognitively normal older adults: The CABLE Study. Ann Clin Transl Neurol, 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF strEM2 in cognitively normal older adults: The CABLE Study. Ann Clin Transl Neurol, 2021. 157: p. 106864. Dakterzada, F., et al., Associations between air pollution and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid ima | 468 | 5. | Goodman, R.A., et al., Prevalence of dementia subtypes in United States Medicare fee-for-service |
| Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</i>. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease</i>. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Uso of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.</i> J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease:</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(1): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and Diomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Association between air pollution and Diomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Association between air pollution and Diomarkers dolutis accuracy Between Elecsys and </i> | 469 | | <i>beneficiaries, 2011-2013</i> . Alzheimers Dement, 2017. 13 (1): p. 28-37. |
| Front Mol Neurosci, 2022. 15: p. 967174. Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease</i>. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</i>. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study</i>. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease</i>. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany</i>. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</i>. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios</i>. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and biomarkers of Alzheimer's disease in cognitively normal older adults: The CABLE study</i>. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Association between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals</i>. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging</i>. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging</i>. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, H.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys as</i> | 470 | 6. | Li, W., et al., A review of respirable fine particulate matter (PM(2.5))-induced brain damage. |
| Huang, W.J., X. Zhang, and W.W. Chen, <i>Role of oxidative stress in Alzheimer's disease</i>. Biomed Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</i>. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study</i>. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease</i>. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany</i>. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Batteman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</i>. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios</i>. Alzheimers Dement (Amst), 2022. 14(1): p. 1252-1763. Li, M., et al., <i>Associations between air pollution and CSF STREM2 in cognitivel normal older adults: The CABLE study</i>. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals</i>. Environ Int, 2021. 157: p. 108644. Dakterzada, F., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging</i>. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Astoinale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies</i>. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter </i> | 471 | | Front Mol Neurosci, 2022. 15 : p. 967174. |
| Rep, 2016. 4(5): p. 519-522. Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease</i>. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study</i>. Environ Int, 2023. 172: p. 107800. 10. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease</i>. Transl Neurodegener, 2022. 11(1): p. 25. 11. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany</i>. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. 12. Batrels, Dis, 2020. 78(3): p. 1137-1148. 13. Bouwman, F.H., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</i>. N Engl J Med, 2012. 367(9): p. 795-804. 14. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study</i>. Ann Clin Transl Neurol, 2022. 14(1): p. e12314. 14. Li, M., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease: in cognitively unimpaired individuals</i>. Environ Int, 2021. 157: p. 106864. 16. Dakterzada, F., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging</i>. Alzheimers Dement, 2018. 14(11): p. 1460-1469. 17. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging</i>. Alzheimers Dement, 2018. 14(11): p. 1460-1469. 18. Goetz, M.E., et al., <i>Retionale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies</i>. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 19. Kheirbek, I., et al., <i>Retornale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies</i>. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 19. Kheirbe | 472 | 7. | Huang, W.J., X. Zhang, and W.W. Chen, Role of oxidative stress in Alzheimer's disease. Biomed |
| Jack, C.R., Jr., et al., <i>NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.</i> Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.</i> J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rotionale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF STREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and Somarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Association between air pollution and biomarkers of Alzheimer's disease in a cognitively unimpaired Individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Acrebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Kheirbek, I., et al., <i>The contribution of motor ve</i> | 473 | | Rep, 2016. 4 (5): p. 519-522. |
| disease. Alzheimers Dement, 2018. 14(4): p. 535-562. Hajat, A., et al., Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF STREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor | 474 | 8. | Jack, C.R., Jr., et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's |
| Hajat, A., et al., <i>Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from</i> <i>the Ginkgo Evaluation of Memory study.</i> Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., <i>Advances in the development of new biomarkers for Alzheimer's disease.</i> Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., <i>Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild</i> <i>Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany.</i> J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From</i> <i>rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older</i> <i>adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(1): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in</i> <i>cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Association fluid biomarkers measured by Elecsys assays compared to</i> <i>amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Schindler, S.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 475 | | <i>disease.</i> Alzheimers Dement, 2018. 14 (4): p. 535-562. |
| the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172: p. 107800. Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concen | 476 | 9. | Hajat, A., et al., Air pollution and plasma amyloid beta in a cohort of older adults: Evidence from |
| Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 477 | | the Ginkgo Evaluation of Memory study. Environ Int, 2023. 172 : p. 107800. |
| Transl Neurodegener, 2022. 11(1): p. 25. Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 478 | 10. | Klyucherev, T.O., et al., Advances in the development of new biomarkers for Alzheimer's disease. |
| Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF STREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 479 | | Transl Neurodegener, 2022. 11 (1): p. 25. |
| Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.</i> Alzheimer Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 480 | 11. | Bartels, C., et al., Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild |
| Alzheimers Dis, 2020. 78(3): p. 1137-1148. Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): p. 89. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 481 | | Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. J |
| Bateman, R.J., et al., <i>Clinical and biomarker changes in dominantly inherited Alzheimer's disease.</i> N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): p. 89. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 482 | | Alzheimers Dis, 2020. 78 (3): p. 1137-1148. |
| N Engl J Med, 2012. 367(9): p. 795-804. Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): p. 89. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 483 | 12. | Bateman, R.J., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. |
| Bouwman, F.H., et al., <i>Clinical application of CSF biomarkers for Alzheimer's disease: From</i> <i>rationale to ratios.</i> Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., <i>Association between air pollution and CSF sTREM2 in cognitively normal older</i> <i>adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., <i>Associations between air pollution and biomarkers of Alzheimer's disease in</i> <i>cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys</i> <i>and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to</i> <i>amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): p. 89. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 484 | | N Engl J Med, 2012. 367 (9): p. 795-804. |
| rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 485 | 13. | Bouwman, F.H., et al., Clinical application of CSF biomarkers for Alzheimer's disease: From |
| Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 486 | | rationale to ratios. Alzheimers Dement (Amst), 2022. 14(1): p. e12314. |
| <i>adults: The CABLE study.</i> Ann Clin Transl Neurol, 2022. 9(11): p. 1752-1763. Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): p. 89. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 487 | 14. | Li, M., et al., Association between air pollution and CSF sTREM2 in cognitively normal older |
| Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environ Int, 2021. 157: p. 106864. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 488 | | adults: The CABLE study. Ann Clin Transl Neurol, 2022. 9 (11): p. 1752-1763. |
| 490 <i>cognitively unimpaired individuals.</i> Environ Int, 2021. 157: p. 106864. 491 16. Dakterzada, F., et al., <i>Assessment of the Concordance and Diagnostic Accuracy Between Elecsys</i> 492 <i>and Lumipulse Fully Automated Platforms and Innotest.</i> Front Aging Neurosci, 2021. 13: p. 604119. 494 17. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to</i> 495 <i>amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. 496 18. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> 497 <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> 499 <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> 502 <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 489 | 15. | Alemany, S., et al., Associations between air pollution and biomarkers of Alzheimer's disease in |
| 491 16. Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. 494 17. Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. 496 18. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): p. 89. 501 20. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 490 | | cognitively unimpaired individuals. Environ Int, 2021. 157 : p. 106864. |
| and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. 604119. 17. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to</i> amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. 18. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 19. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> <i>public health impacts in New York City: a health burden assessment</i>. Environ Health, 2016. 15(1): p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 491 | 16. | Dakterzada, F., et al., Assessment of the Concordance and Diagnostic Accuracy Between Elecsys |
| 493 604119. 494 17. Schindler, S.E., et al., <i>Cerebrospinal fluid biomarkers measured by Elecsys assays compared to</i> 495 <i>amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. 496 18. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> 497 <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> 499 <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> 502 <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 492 | | and Lumipulse Fully Automated Platforms and Innotest. Front Aging Neurosci, 2021. 13: p. |
| 494 17. Schindler, S.E., et al., <i>Cerebrospinal fulla biomarkers measured by Elecsys assays compared to</i> 495 <i>amyloid imaging.</i> Alzheimers Dement, 2018. 14(11): p. 1460-1469. 496 18. Goetz, M.E., et al., <i>Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain</i> 497 <i>Studies.</i> Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> 499 <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> 502 <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 493 | 47 | 604119. |
| 495 amyloid imaging. Alzheimers Dement, 2018. 14(11): p. 1460-1469. 496 18. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain 497 Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter 499 public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km 6rids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 494 | 17. | Schindler, S.E., et al., Cerebrospinal fluid biomarkers measured by Elecsys assays compared to |
| 496 18. Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain 497 Studies. Neuroepidemiology, 2019. 53(3-4): p. 187-200. 498 19. Kheirbek, I., et al., The contribution of motor vehicle emissions to ambient fine particulate matter 499 public health impacts in New York City: a health burden assessment. Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km 502 Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 495 | 10 | amyloid imaging. Alzheimers Dement, 2018. 14 (11): p. 1460-1469. |
| 497 Studies. Neuroepidemiology, 2019. 55(3-4): p. 187-200. 498 19. Kheirbek, I., et al., <i>The contribution of motor vehicle emissions to ambient fine particulate matter</i> 499 <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> 502 <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 490 | 18. | Goetz, M.E., et al., Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies, Neurophidemiology, 2010, F2 (2,4), p. 197,200 |
| 498 19. Knell bek, 1., et al., <i>The contribution of motor venicle emissions to uniblent file particulate matter</i> 499 <i>public health impacts in New York City: a health burden assessment.</i> Environ Health, 2016. 15(1): 500 p. 89. 501 20. Di, Q., et al., <i>Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km</i> 502 <i>Grids, v1 (2000 - 2016).</i> 2021, NASA Socioeconomic Data and Applications Center (SEDAC): 503 Di Jone Matter | 497 | 10 | Studies. Neuroepidemiology, 2019. 53 (3-4): p. 187-200. |
| public health impacts in New York City. a health burden assessment. Environ Health, 2018. 15(1). p. 89. Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 430 100 | 19. | nuclinger, I., et al., The contribution of motor venicle emissions to amplent fine particulate matter |
| 500p. 85.50120.Di, Q., et al., Daily and Annual PM2.5 Concentrations for the Contiguous United States, 1-km502Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC):503Duited back Nucleon | 433 500 | | n 20 |
| 502 Grids, v1 (2000 - 2016). 2021, NASA Socioeconomic Data and Applications Center (SEDAC): | 500 | 20 | p. 03. Di O. et al. Daily and Annual BM2.5 Concentrations for the Continuous United States 1 km |
| 502 Onus, vi (2000 - 2010). 2021, NASA Socioeconomic Data anu Applications Center (SEDAC). | 501 | 20. | Grids v1 (2000 - 2016) 2021 NASA Socioeconomic Data and Applications Center (SEDAC). |
| | 502 | | Palisades New York |

| 504 | 24 | Di O and A and the based of the DM(2,5) and the line of the second state of the second |
|-------------|-----|--|
| 504 | 21. | DI, Q., et al., An ensemble-based model of Pivi(2.5) concentration across the contiguous United |
| 505 | | States with high spatiotemporal resolution. Environ Int, 2019. 130 : p. 104909. |
| 506 | 22. | Christensen, G.M., et al., Fine particulate air pollution and neuropathology markers of |
| 507 | | Alzheimer's disease in donors with and without APOE epsilon4 alleles - results from an autopsy |
| 508 | | <i>cohort.</i> medRxiv, 2023. |
| 509 | 23. | Jeremy A. Sarnat, A.T.R., Donghai Liang, Jennifer L. Moutinho, Rachel Golan, Rodney J. Weber, |
| 510 | | Dong Gao, Stefanie Ebelt Sarnat, Howard H. Chang, Roby Greenwald, Tianwei Yu, Developing |
| 511 | | Multipollutant Exposure Indicators of Traffic Pollution: The Dorm Room Inhalation to Vehicle |
| 512 | | Emissions (DRIVE) Study. Res Rep Health Eff Inst., 2018. Research Report 196. |
| 513 | 24. | Zhai, X.R., G. A.; Sampath, P.; Mulholland, A. J.; Kim, B; Kim, Y.; D'Onofrio, D., Calibrating R-LINE |
| 514 | | model results with observational data to develop annual mobile source air pollutant fields at fine |
| 515 | | spatial resolution: Application in Atlanta. Atmospheric Environment, 2016. 147 : p. 446-457. |
| 516 | 25. | Teunissen, C.E., et al., A consensus protocol for the standardization of cerebrospinal fluid |
| 517 | | collection and biobanking. Neurology, 2009. 73(22): p. 1914-22. |
| 518 | 26. | Doecke, J.D., et al., Elecsys CSF biomarker immunoassays demonstrate concordance with |
| 519 | | amyloid-PET imaging. Alzheimers Res Ther, 2020. 12 (1): p. 36. |
| 520 | 27. | Ltd, F.HL.R. The Power of Elecsys [®] in Alzheimer's disease. 2023; Available from: |
| 521 | | https://diagnostics.roche.com/global/en/article-listing/health-topics/neurology/the-power-of- |
| 522 | | elecsys-in-alzheimers-disease.html. |
| 523 | 28. | Hansson, O., et al., CSF biomarkers of Alzheimer's disease concord with amvloid-beta PET and |
| 524 | | predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI |
| 525 | | <i>cohorts</i> . Alzheimers Dement. 2018. 14 (11): p. 1470-1481. |
| 526 | 29. | Blennow, K., et al., Predicting clinical decline and conversion to Alzheimer's disease or dementia |
| 527 | | using novel Elecsys Abeta(1-42), nTay and tTay CSE immunoassays. Sci Rep. 2019. 9(1): p. 19024. |
| 528 | 30 | Li 7, et al. Neighborhood characteristics as confounders and effect modifiers for the association |
| 529 | | between air pollution exposure and subjective coanitive functioning. Environ Res. 2022. 212 (Pt |
| 530 | | A): n 113221 |
| 531 | 31 | Garrett ST et al Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and |
| 532 | 51. | Associated Cutoffs for Mild Cognitive Imnairment JAMA Netw Open 2019 2(12): n e1917363 |
| 533 | 32 | Every M et al. Body mass index is associated with biological CSE markers of core brain |
| 534 | 52. | nathology of Alzheimer's disease. Neurobiol Aging 2012 33 (8): n 1599-608 |
| 535 | 22 | Ean IX M Wen and K Li Associations between obesity and neighborhood socioeconomic |
| 536 | 55. | status: Variations by gender and family income status SSM Popul Health 2020 10 : p 100529 |
| 527 | 21 | Singh G K Area deprivation and widening inequalities in US mortality 1060-1008 Am L Public |
| 538 | 54. | Health 2003 03 (7): n 1137-//3 |
| 520 | 25 | Campbell M.P. et al. P-tau/Abeta/2 and Abeta/2/40 ratios in CSE are equally predictive of |
| 540 | 55. | amyloid PET status Alzheimers Dement (Amst) 2021 12 (1): n e12100 |
| 540 | 26 | Univiolar PET status. Alzheimers bement (Anist), 2021. 13 (1). p. e12150. |
| 541 | 50. | A2/40 ratio in the diagnosis of Alzhoimar's Disagsa, Alzhoimars Bos Thor. 2010, 11 (1): p. 24 |
| 542 | 27 | 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimer's Res Thei, 2019. 11(1), p. 54. |
| | 57. | Raiaguilaii, F., et al., contributions to titles unibient purticulate matter (Pivi). A systematic |
| 544 | | And the source contributions at global level. Atmospheric Environment, 2015. 120. p. 475- |
| 545 | 20 | 403. Sutaban C.L. at al. Longituding Corphrogning Fluid Diamarkar Changes in Proglinical Alphaimer |
| 540 | 38. | Sulphen, C.L., et al., Longitudinal Cerebrospinal Flata Biomarker Changes in Preclinical Alzheimer |
| 547 | 20 | Disease During Middle Age. JAMA Neurol, 2015. 72(9): p. 1029-42. |
| 548 F 40 | 39. | Au, J., et al., Photochemical impacts on the toxicity of Piviz.5. Critical Reviews in Environmental |
| 549 | 40 | Science and rechnology, 2022. 52 (1): p. 130-156. |
| 550 | 40. | YOU, K., Y.S. HO, and K.C. Chang, The pathogenic effects of particulate matter on |
| 551 | | neuroaegeneration: a review. J Biomed Sci, 2022. 29 (1): p. 15. |
| 55Z | | |

| Characteristics ^d | Overall (N=1113) |
|---|---------------------|
| Age (years) | |
| Mean (SD) | 61.7 (6.73) |
| Median [Min, Max] | 62.0 [45.0, 77.0] |
| Gender | |
| Female | 775 (69.6%) |
| Body Mass Index (kg/m²) | |
| Mean (SD) | 25.5 (3.55) |
| Median [Min, Max] | 25.3 [16.8, 38.4] |
| Race/Ethnicity ^a | |
| White/Caucasian | 943 (84.7%) |
| Black/African American | 121 (10.9%) |
| Other | 49 (4.4%) |
| Hispanic | |
| Yes | 32 (2.9%) |
| Educational Attainment ^b | |
| Less than college | 147 (13.2%) |
| College | 478 (42.9%) |
| Master or higher | 488 (43.8%) |
| Area Deprivation Index ^c | |
| Mean (SD) | 29.4 (20.1) |
| Median [Min, Max] | 25.0 [1.00, 93.0] |
| APOE-ε4 allele carriership | |
| No allele | 591 (53.1%) |
| 1 allele | 241 (21.7%) |
| 2 alleles | 23 (2.1%) |
| Missing | 258 (23.2%) |
| Air pollution concentration | |
| 1 yr. ambient PM _{2.5} (μg/m³) | |
| Mean (SD) | 9.52 (0.764) |
| Median [Min, Max] | 9.52 [5.63, 13.2] |
| IQR | 0.845 |
| 3 yr. ambient PM _{2.5} (μg/m³) | |
| Mean (SD) | 9.85 (0.832) |

Table 1 Baseline descriptive characteristics for EHBS study participants (≥45 years of age).

| Characteristics ^d | Overall (N=1113) |
|---|---------------------|
| Median [Min, Max] | 9.96 [5.99, 12.0] |
| IQR | 1.10 |
| 5 yr. ambient PM₂.₅ (μg/m³) | |
| Mean (SD) | 9.96 (0.735) |
| Median [Min, Max] | 10.1 [6.41, 12.0] |
| IQR | 0.945 |
| 1 yr. traffic PM _{2.5} (μg/m³) | |
| Mean (SD) | 1.15 (0.464) |
| Median [Min, Max] | 1.10 [0.155, 5.06] |
| IQR | 0.523 |
| Missing <i>n</i> (%) | 33 (3.0%) |
| 3 yr. traffic PM _{2.5} (μg/m³) | |
| Mean (SD) | 1.26 (0.455) |
| Median [Min, Max] | 1.23 [0.175, 5.56] |
| IQR | 0.479 |
| Missing <i>n</i> (%) | 33 (3.0%) |
| 5 yr. traffic PM _{2.5} (μg/m³) | |
| Mean (SD) | 1.25 (0.432) |
| Median [Min, Max] | 1.21 [0.168, 5.38] |
| IQR | 0.447 |
| Missing <i>n</i> (%) | 33 (3.0%) |

^aSelf-reported race/ethnicity was categorized into 3 groups: White/Caucasian,
 Black/African American, and Other which includes both minority and mixed ancestry
 groups.
 ^bEducational attainment was self-report and included less than high school, high
 school/CED, some college, associate's degree, backelor's degree, and

558 school/GED, some college, associate's degree, bachelor's degree, master's degree, and 559 a professional degree (e.g., Ph.D.).

^cDerived from factor analysis and validated to the Census Block Group neighborhood
 level with factors for the theoretical domains of income, education, employment, and
 housing quality; higher scores indicate higher levels of "disadvantage."

^dAbbreviations: yr., Year; SD, standard deviation; Min, minimum; Max, maximum; IQR,
 interquartile range; μg, Microgram; m³, meters cubed.

| AD CSF concentrations and (+) cut-off | Total (N=1113) |
|---------------------------------------|-------------------------|
| Αβ ₄₂ (pg/mL) | |
| Mean (SD) | 1200 (382) |
| Median [Min, Max] | 1210 [200, 1700] |
| IQR | 692.3 |
| tTau (pg/mL) | |
| Mean (SD) | 187 (70.9) |
| Median [Min, Max] | 174 [80.0, 799] |
| IQR | 79.6 |
| pTau (pg/mL) | |
| Mean (SD) | 16.7 (7.16) |
| Median [Min, Max] | 15.2 [8.00, 83.8] |
| IQR | 7.63 |
| tTau/Aβ₄₂ (pg/mL) | |
| Mean (SD) | 0.171 (0.107) |
| Median [Min, Max] | 0.141 [0.0818, 1.72] |
| pTau/Aβ₄₂ (pg/mL) | |
| Mean (SD) | 0.0154 (0.0116) |
| Median [Min, Max] | 0.0123 [0.00692, 0.200] |
| Αβ ₄₂ | |
| (+) | 402 (36.1%) |
| tTau | |
| (+) | 68 (6.1%) |
| рТаи | |
| (+) | 65 (5.8%) |
| tTau/Aβ ₄₂ | |
| (+) | 87 (7.8%) |
| pTau/Aβ ₄₂ | |
| (+) | 118 (10.6%) |

566 **Table 2** Baseline AD CSF Outcomes at enrollment between 2016 and 2020.

^aAD CSF portfolio positive (+) vs (-) cut-offs (A $\beta_{42} \le 1030$ pg/ml; tTau >300 pg/mL;

568 pTau >27 pg/mL; tTau/Aβ₄₂ >0.28pg/mL; pTau/Aβ₄₂ >0.023pg/mL)





571 **Figure 1** Map of the geographic distribution, each dot representing a study participant, of our study

- population and annual ambient residential $PM_{2.5}$ (in $\mu g/m^3$) exposure by quantile (A) (N=1,113) or
- annual traffic-related residential $PM_{2.5}$ exposure (min-max) with easy breaks (**B**) (N=1,080).
- 574
- 575
- 576
- 577



579 Figure 2 Effect Estimate (± 95% CI) of 1, 3, and 5-year ambient (A–E) (N=1,113) and traffic-related

- 580 (**F**-J) (N=1,080) PM_{2.5} exposure on AD CSF Biomarker concentrations (in pg/mL) (A β_{42} , tTau, pTau,
- tTau/A β_{42} , and pTau/A β_{42}). All estimates are standardized and adjusted for gender, age, N-SES,
- 582 ethnicity, educational attainment, and BMI. The dashed line indicates the significance threshold: 0
- 583 for linear regression.
- 584



586

- 587 **Figure 3** Odds ratio (± 95% CI) for the association between 1, 3, and 5-year ambient (**A**–**E**)
- 588 (N=1,113) and traffic-related (**F**–**J**) (N=1,080) PM_{2.5} exposure and AD CSF Biomarkers positive (+)
- 589 cut-offs (Aβ₄₂, tTau, pTau, tTau/Aβ₄₂, and pTau/Aβ₄₂). All estimates are adjusted for gender, age, N-
- 590 SES, ethnicity, educational attainment, and BMI. The dashed line indicates the significance
- 591 threshold: 1 for logistic regression.



593

Figure 4 Effect (± 95% CI) of yearly ambient PM_{2.5} exposure on A β_{42} CSF concentrations (in pg/mL)

595 by *APOE*-ε4 carriership (**A**), AD family history (**B**), ADI (**C**), Gender (**D**), and Age (**E**). Presented as 596 overall and stratified effects for dichotomous variables and as continuous for Age, with interaction p-

597 values depicted on each graph. The dashed line indicates the significance threshold: 0 for linear

regression. The overall effect in **Figure 4A** (N=855) differs slightly from **Figure 4B-D** (N=1113) due

599 to the decreased sample size after including only participants with APOE genotype data.